Searched for
DRL STOCKS
Should you buy the dip? Strategist Anand James shares his weekly stock strategyMarket expert Anand James suggests caution following recent volatility. He notes the Nifty needs to break above 24,140 for a confirmed upsw...- Market Outlook: Rupak De’s top 3 trading stock picks for the week aheadGeopolitical tensions, rising crude oil, and a weakening rupee are fueling market volatility, according to Rupak De of LKP Securities. He n...
- Dr Reddy's shares rally 4% as Nuvama upgrades rating to buyDr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Re...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- What CLSA says on Lupin; Morgan Stanley on DRL, Godrej ConsumerIn the case of DRL, Morgan Stanley said that the drug maker continued to deliver granular growth and that the growth trend should continue ...
- DRL's many pluses negated by regulatory hitThe operating margin of 27% has been above the company's long term guidance of 25%. However, the good performance was dented after the comp...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- New initiatives, faster Sputnik rollout can lift DRL stockRevenues rose 12% and net profit declined by a percent over the prior year. Ebitda margin dropped 560 bps to 20.7%. The disappointing perfo...
- Dr Reddy's lines up Rs 1,000 crore capex for current fiscal yearThe Hyderabad based firm invested about Rs 1,000 crore in the 2020-21 fiscal year.
- How did India's Big Pharma fare in the December Quarter?Sun Pharma reported its highest-ever quarterly sales, and Cipla posted the highest-ever Ebitda margin in the company's recent history. Lupi...
- Why a new expat CEO may be good news for Dr Reddy’sDrug maker undergoing major changes under Erez Islraeli
- Why investors should be more worried about Lupin than DRLMain focus area remains complex generics where other cos have an advantage
- DRL stock slips 5% after US court orderThe scrip was 5.30 per cent down at Rs 2,565.60 at around 02.12 pm.
- Dr Reddy’s, feeling the pain now, looks better from long-term viewThe 'sell' recommendations on the stock more than doubled from 7 to 17 with leading brokerages downgrading the stock.
- Brokerages raise price target on Dr Reddy's to as high as Rs 2,720 on FDA nodBrokerages see the FDA approval to Dr Reddy’s Laboratories (DRL) for generic Vidaza as a positive for the company.
- Dr Reddy’s Laboratories: Long-term prospects look good despite hiccup in Q1DRL’s contract research and manufacturing business also posted subdued sales, showing just a 6% growth, due to fewer launches by DRL’s clie...
- Growth in US, local market to pep up DRLDr Reddy’s Laboratories (DRL), India’s third-largest pharma company, has seen a sharp rise of 25% in its stock price over the past fifteen ...
- Dr Reddy's in talks with Glaxo for stake saleMost MNCs are focusing on India and emerging markets to sustain their growth as the US and Europe markets slow down.
- Analyst's Pick: Dr Reddy's LaboratoriesCitigroup recommends 'Hold' rating on Dr Reddy’s Laboratories with a target price of Rs 547.
- Dr Reddy's looks at settling Sanofi dispute out of courtPharma major Dr Reddy’s Laboratories (DRL) is contemplating an out-of-court settlement with the French company Sanofi-Aventis for anti-alle...
Load More
